Urine Osmolality Is a Potential Marker of Longer-term Efficacy of Tolvaptan in ADPKD: A Post-hoc Analysis.

Vijay D Ivaturi Jogarao V S Gobburu Bruce Leslie Xiaofeng WangPravin Jadhav

Published in: Kidney360 (2024)

Change in Uosm is a potential biomarker for long-term treatment outcome with tolvaptan and might expedite clinical trials and treatment decision-making for drugs with similar mechanisms of action.

Keyphrases

polycystic kidney disease
clinical trial
decision making
acute heart failure
preterm infants
randomized controlled trial
heart failure
gestational age
phase ii
climate change
replacement therapy
preterm birth
phase iii
double blind
placebo controlled